JP2010503640A - オリゴヌクレオチド非ウイルスデリバリーシステム - Google Patents

オリゴヌクレオチド非ウイルスデリバリーシステム Download PDF

Info

Publication number
JP2010503640A
JP2010503640A JP2009527838A JP2009527838A JP2010503640A JP 2010503640 A JP2010503640 A JP 2010503640A JP 2009527838 A JP2009527838 A JP 2009527838A JP 2009527838 A JP2009527838 A JP 2009527838A JP 2010503640 A JP2010503640 A JP 2010503640A
Authority
JP
Japan
Prior art keywords
composition
sirna
molecular weight
low molecular
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010503640A5 (zh
Inventor
アーター スベン アターソン，パー
マーモウド イッサ，モハメド
プロカツコバ ストランド，サビナ
モーテン バルム，ジエル
Original Assignee
エフエムシー バイオポリマー エイエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフエムシー バイオポリマー エイエス filed Critical エフエムシー バイオポリマー エイエス
Publication of JP2010503640A publication Critical patent/JP2010503640A/ja
Publication of JP2010503640A5 publication Critical patent/JP2010503640A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2009527838A 2006-09-15 2007-09-14 オリゴヌクレオチド非ウイルスデリバリーシステム Pending JP2010503640A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84472906P 2006-09-15 2006-09-15
PCT/EP2007/059740 WO2008031899A2 (en) 2006-09-15 2007-09-14 Oligonucleotide non-viral delivery systems

Publications (2)

Publication Number Publication Date
JP2010503640A true JP2010503640A (ja) 2010-02-04
JP2010503640A5 JP2010503640A5 (zh) 2010-07-29

Family

ID=39092312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527838A Pending JP2010503640A (ja) 2006-09-15 2007-09-14 オリゴヌクレオチド非ウイルスデリバリーシステム

Country Status (9)

Country Link
US (1) US7875449B2 (zh)
EP (1) EP2061516A2 (zh)
JP (1) JP2010503640A (zh)
KR (1) KR20090058562A (zh)
CN (1) CN101588821A (zh)
BR (1) BRPI0716925A2 (zh)
CA (1) CA2662560A1 (zh)
IL (1) IL197497A (zh)
WO (1) WO2008031899A2 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511255A (ja) * 2013-02-28 2016-04-14 チョン クン ダン ファーマシューティカル コーポレーション キトサンおよび液晶形成物質を含む遺伝子伝達用組成物
WO2018216792A1 (ja) * 2017-05-26 2018-11-29 公益財団法人川崎市産業振興財団 血中におけるｒｎａの安定性の改善剤および投与方法
US10646579B2 (en) 2015-11-04 2020-05-12 Tme Therapeutics Inc. Complex comprising RNAi molecule and N-acetylated chitosan
JP2023519754A (ja) * 2020-06-24 2023-05-12 珠海舒桐医療科技有限公司 膣ゲル製剤及びその調製方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295045A1 (en) * 2006-07-07 2011-03-16 Aarhus Universitet Nanoparticles for nucleic acid delivery
EP2326351B1 (en) 2008-08-19 2017-12-27 Nektar Therapeutics Conjugates of small-interfering nucleic acids
WO2013059617A1 (en) * 2011-10-21 2013-04-25 Ndsu Research Foundation Liposome compositions and methods of use
RU2014132564A (ru) 2012-01-27 2016-03-20 Ф. Хоффманн-Ля Рош Аг Хитозан, ковалентно связанный с низкомолекулярным антагонистом интегрина, для нацеленной доставки

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533078A (ja) * 2002-06-20 2005-11-04 バイオオーリアンス ファーマ 少なくとも１つのポリマー及び少なくとも１つの正帯電多糖類の均一サイズのナノ粒子を含むベクター化システム及びその調製方法
JP2005533016A (ja) * 2002-05-03 2005-11-04 エフエムシー バイオポリマー エイエス 非ウイルス性遺伝子送達システム

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922260A (en) * 1973-08-24 1975-11-25 Quintin P Peniston Process for depolymerization of chitosan
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
SE9904475D0 (sv) 1999-12-08 1999-12-08 Artursson Nucleic acid delivery system
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
NO317654B1 (no) * 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav.
US20070116767A1 (en) 2003-02-14 2007-05-24 Mohapatra Shyam S Chitosan-microparticles for ifn gene delivery
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
US8399025B2 (en) * 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
US20090075383A1 (en) * 2005-11-04 2009-03-19 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
EP2034954B1 (en) * 2006-03-30 2019-02-20 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
EP2295045A1 (en) * 2006-07-07 2011-03-16 Aarhus Universitet Nanoparticles for nucleic acid delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533016A (ja) * 2002-05-03 2005-11-04 エフエムシー バイオポリマー エイエス 非ウイルス性遺伝子送達システム
JP2005533078A (ja) * 2002-06-20 2005-11-04 バイオオーリアンス ファーマ 少なくとも１つのポリマー及び少なくとも１つの正帯電多糖類の均一サイズのナノ粒子を含むベクター化システム及びその調製方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012052387; ＧＡＯ　Ｓ　ＥＴ　ＡＬ: 'Ｔａｒｇｅｔｉｎｇ　ｄｅｌｉｖｅｒｙ　ｏｆ　ｏｌｉｇｏｎｕｃｌｅｏｔｉｄｅ　ａｎｄ　ｐｌａｓｍｉｄ　ＤＮＡ　ｔｏ　ｈｅｐａｔｏｃｙｔｅ　ｖｉａ　ｇａｌａｃｔｏｓｙｌａｔｅｄ　ｃｈｉｔｏｓａｎ　ｖｅｃｔ' ＥＵＲＯＰＥＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＰＨＡＲＭＡＣＥＵＴＩＣＳ　ＡＮＤ　ＢＩＯＰＨＡＲＭＡＣＥＵＴＩＣＳ ｖｏｌ．　６０，　ｎｏ．　３, 200508, ｐａｇｅｓ　３２７-３３４ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511255A (ja) * 2013-02-28 2016-04-14 チョン クン ダン ファーマシューティカル コーポレーション キトサンおよび液晶形成物質を含む遺伝子伝達用組成物
US11318215B2 (en) 2013-02-28 2022-05-03 Chong Kun Dang Pharmaceutical Corp. Composition for gene delivery comprising chitosan and liquid crystal formation material
US10646579B2 (en) 2015-11-04 2020-05-12 Tme Therapeutics Inc. Complex comprising RNAi molecule and N-acetylated chitosan
WO2018216792A1 (ja) * 2017-05-26 2018-11-29 公益財団法人川崎市産業振興財団 血中におけるｒｎａの安定性の改善剤および投与方法
JPWO2018216792A1 (ja) * 2017-05-26 2020-03-26 公益財団法人川崎市産業振興財団 血中におけるｒｎａの安定性の改善剤および投与方法
JP7237825B2 (ja) 2017-05-26 2023-03-13 公益財団法人川崎市産業振興財団 血中におけるｒｎａの安定性の改善剤および投与方法
JP2023519754A (ja) * 2020-06-24 2023-05-12 珠海舒桐医療科技有限公司 膣ゲル製剤及びその調製方法

Also Published As

Publication number Publication date
IL197497A (en) 2013-06-27
BRPI0716925A2 (pt) 2013-09-17
IL197497A0 (en) 2009-12-24
KR20090058562A (ko) 2009-06-09
WO2008031899A3 (en) 2008-05-08
EP2061516A2 (en) 2009-05-27
CN101588821A (zh) 2009-11-25
US7875449B2 (en) 2011-01-25
US20080131371A1 (en) 2008-06-05
WO2008031899A2 (en) 2008-03-20
CA2662560A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
Matsumoto et al. Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery
US7875449B2 (en) Oligonucleotide non-viral delivery systems
Rudzinski et al. Chitosan as a carrier for targeted delivery of small interfering RNA
CN112153985A (zh) 用于颗粒制剂的防冻剂
Malmo et al. siRNA delivery with chitosan nanoparticles: Molecular properties favoring efficient gene silencing
Averick et al. Preparation of cationic nanogels for nucleic acid delivery
US11007279B2 (en) Highly stable biodegradable gene vector platforms for overcoming biological barriers
Rojanarata et al. Chitosan-thiamine pyrophosphate as a novel carrier for siRNA delivery
Khurana et al. siRNA delivery using nanocarriers-an efficient tool for gene silencing
Wang et al. Photoluminescent and biodegradable polycitrate-polyethylene glycol-polyethyleneimine polymers as highly biocompatible and efficient vectors for bioimaging-guided siRNA and miRNA delivery
Zhou et al. Targeted delivery of secretory promelittin via novel poly (lactone‐co‐β‐amino ester) nanoparticles for treatment of breast cancer brain metastases
David-Naim et al. Polymeric nanoparticles of siRNA prepared by a double-emulsion solvent-diffusion technique: Physicochemical properties, toxicity, biodistribution and efficacy in a mammary carcinoma mice model
Vader et al. Polymeric carrier systems for siRNA delivery
Oliveira et al. Transfection efficiency of chitosan and thiolated chitosan in retinal pigment epithelium cells: A comparative study
JP2020172534A (ja) 合成脳浸透遺伝子ベクターの操作
US8987215B2 (en) Composition for use in gene therapy
US20020016304A1 (en) Carrier for stabilizing nucleic acid
Opanasopit et al. Nucleic acid delivery with chitosan hydroxybenzotriazole
Mobarakeh et al. Modification of SPION nanocarriers for siRNA delivery: a therapeutic strategy against HIV infection
Zhang et al. Effective mRNA Inhibition in PANC-1 Cells in Vitro Mediated via an mPEG–SeSe–PEI Delivery System
RU2820713C2 (ru) Криопротективные агенты для содержащих частицы составов
TÜZMEN et al. Attractive approaches in siRNA delivery using polymer bio-based carrier systems.
CN114829615A (zh) 包含聚丙烯亚胺的非病毒载体
Gouveia Exploring the potential of fully Biodegradable PEG-Dendrimers as Nanocarriers of Different siRNA Sequences for Dual Delivery
Yalınca et al. ATTRACTIVE APPROACHES in DRUG DELIVERY: BIO-BASED CARRIERS for siRNA TARGETING

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100611

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121009

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130312